Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
The company will showcase ImmunoID NeXT™, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT™ can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.
Following is a list of abstracts that will be presented at the meeting.
Scientific Poster Presentations
Poster Number & Category |
Title & Presenter |
Day & Time |
Location |
|||
P77 Biomarkers, Immune Monitoring, and Novel Technologies |
Comprehensive profiling of tumor-immune interaction in anti-PD-1 treated melanoma patients reveals subject-specific tumor escape mechanisms Presenter: Charles Abbott, Ph.D. |
November 8: |
Poster Hall: Prince George AB |
|||
P72 Biomarkers, Immune Monitoring, and Novel Technologies |
Comprehensive and accurate prediction of presented neoantigens using ImmunoID NeXT and advanced machine learning algorithms Presenters: Dattatreya Mellacheruvu, Ph.D. and Rachel Pyke, Ph.D. |
November 9: |
Poster Hall: Prince George AB |
|||
P96 Biomarkers, Immune Monitoring, and Novel Technologies |
T-cell receptor alpha and beta repertoire profiling using an augmented transcriptome Presenter: Eric Levy, Ph.D. |
November 9: |
Poster Hall: Prince George AB |
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005817/en/
Source:
Investor Relations Contact for Personalis:
Caroline Corner
investors@personalis.com
www.westwicke.com
415-202-5678
Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300